» Articles » PMID: 17883935

Comparison of Drug Abuse in Germany and China

Overview
Specialty Pharmacology
Date 2007 Sep 22
PMID 17883935
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Drug abuse has a long, but also different history in Germany and China. The Opium War largely influenced the history of China in 19th century; however, China was once recognized as a drug-free nation for 3 decades from the 1950s to the 1980s. Drug abuse has spread quickly since re-emerging as a national problem in China in the late 1980s. The number of registered drug abusers increased from 70 000 in 1990 to more than 1 million by the end of 2005. In past decades, illicit drug trafficking and production have swept most provinces in China, and drug abuse has caused many problems for both abusers and the community. One major drug-related problem is the spread of HIV, which has caused major social and economic damage in China. Germany, the largest developed European country, also faces the drug and addiction problem. Germany has about 150 000 heroin addicts, for whom HIV/AIDS has become a serious threat since the mid 1980s. To control the drug problem, the German Government adopted the pAction Plan on Drugs and Addictionq in 2003; the China Central Government approved a similar regulation in the antidrug campaign in 2005. Germany has experience in reducing drug-related harm. The methadone maintenance treatment (MMT) program has run for more than 20 years and the public has become more tolerant of addicts. In 2003, China began the MMT program for controlling the spread of HIV/AIDS. It is necessary for China to learn from developed countries to acquire success in its antidrug campaign. In this review, we will go over the differences and similarities in drug abuse between Germany and China. The differences are related to history, population and economics, drug policy context, drug laws, HIV/hepatitis C virus infection, the MMT program and so on. These 2 nations have drug abuse problems with different histories and currently use different approaches to handle illicit drug marketing and use. The legal penalties for illicit drug offences reflect the social differences of these 2 nations with respect to the seriousness of particular types of crimes. The characteristics of the MMT program may also influence patterns of drug abuse in these 2 nations and China should improve the MMT program based on the successful model in Europe, the USA, and Australia. We recommend more dialogue and collaboration between Germany and China.

Citing Articles

Newly estimated disability weights for 196 health states in Hubei Province, China.

Zhou M, Zhang L, He T, Zhu S, Tang Y, Li Q Popul Health Metr. 2024; 22(1):37.

PMID: 39696426 PMC: 11657749. DOI: 10.1186/s12963-024-00359-5.


Patterns of childhood trauma and psychological distress among injecting heroin users in China.

Wang Z, Du J, Sun H, Wu H, Xiao Z, Zhao M PLoS One. 2011; 5(12):e15882.

PMID: 21209959 PMC: 3012100. DOI: 10.1371/journal.pone.0015882.


[Burden of disease and level of patient's medical care in substitution treatment for opiates].

Muller M, Pichler M, Martin G, Plorer D, Winter C, Pogarell O Med Klin (Munich). 2009; 104(12):913-7.

PMID: 20039157 DOI: 10.1007/s00063-009-1196-2.


Effects of cannabinoid CB1 receptor antagonist rimonabant in consolidation and reconsolidation of methamphetamine reward memory in mice.

Yu L, Wang X, Zhao M, Liu Y, Li Y, Li F Psychopharmacology (Berl). 2009; 204(2):203-11.

PMID: 19148622 DOI: 10.1007/s00213-008-1450-y.


Drug abuse in China: past, present and future.

Lu L, Fang Y, Wang X Cell Mol Neurobiol. 2007; 28(4):479-90.

PMID: 17990098 PMC: 11515005. DOI: 10.1007/s10571-007-9225-2.

References
1.
Lowinger P . The solution to narcotic addiction in the People's Republic of China. Am J Drug Alcohol Abuse. 1977; 4(2):165-78. DOI: 10.3109/00952997709002758. View

2.
Sun Z, Ming L, Zhu X, Lu J . Prevention and control of hepatitis B in China. J Med Virol. 2002; 67(3):447-50. DOI: 10.1002/jmv.10094. View

3.
Carroll K, Ball S, Nich C, Martino S, Frankforter T, Farentinos C . Motivational interviewing to improve treatment engagement and outcome in individuals seeking treatment for substance abuse: a multisite effectiveness study. Drug Alcohol Depend. 2005; 81(3):301-12. PMC: 2386852. DOI: 10.1016/j.drugalcdep.2005.08.002. View

4.
Rosenberg H, Melville J, McLean P . Acceptability and availability of pharmacological interventions for substance misuse by British NHS treatment services. Addiction. 2002; 97(1):59-65. DOI: 10.1046/j.1360-0443.2002.00059.x. View

5.
Backmund M, Reimer J, Meyer K, Gerlach J, Zachoval R . Hepatitis C virus infection and injection drug users: prevention, risk factors, and treatment. Clin Infect Dis. 2005; 40 Suppl 5:S330-5. DOI: 10.1086/427475. View